IP Library › Granted Patent US 7,396,828
Granted Patent B2
US 7,396,828 · App. 11/111,201 · Granted Jul 8, 2008

PI-3 kinase inhibitor prodrugs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,396,828
App. No.
11/111,201
Granted
Jul 8, 2008
Kind
B2
Abstract

The invention provides prodrugs of inhibitors of PI-3 kinase. The compounds are LY294002 and analogs thereof comprising a reversibly quaternized amine.

Claims (3)

1. A method of treating lung cancer or brain cancer in a subject comprising administering to a subject in need thereof a compound or salt thereof, wherein the compound is of the formula:

2. A compound having the formula:

or a salt thereof.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2013
From: PARK FUNDING, LLC
To: SIGNALRX PHARMACEUTICALS, INC.
Reel/Frame 030305/0819 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR NAME PREVIOUSLY RECORDED ON REEL 023915 FRAME 0283. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT ASSIGNOR NAME IS SEMAFORE PHARMACEUTICALS, INC.. Recorded Aug 17, 2011
From: SEMAFORE PHARMACEUTICALS, INC.
To: PARK FUNDING, LLC
Reel/Frame 026764/0070 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2010
From: SEMAPHORE PHARMACEUTICALS, INC.
To: PARK FUNDING, LLC
Reel/Frame 023915/0283 →
SECURITY AGREEMENT Recorded May 29, 2009
From: SEMAFORE PHARMACEUTICALS, INC.
To: PARK FUNDING, LLC
Reel/Frame 022746/0638 →